A practical reference on incretin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-06 and is reviewed periodically as new material appears.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Another form of bioprinting involves an inkjet printer, which is primarily used in biomedical settings. This method prints detailed proteins and nucleic acids. Hydrogels are commonly selected as the bioink. Cells can be printed on to a selected surface media to proliferate and ultimately differentiate. A drawback of this printing method is the ability of the bioinks such as hydrogels to clog the printing nozzle, due to their high viscosity. Ideal inkjet bioprinting involves using a low polymer viscosity (ideally below 10 centipoise), low cell density (<10 million cells/mL), and low structural heights (<10 million cells/mL).
When the B cells get activated, class switching can occur. The class switching involves switch regions that made up of multiple copies of short repeats (GAGCT and TGGGG). These switches occur at the level of rearrangements of the DNA because there is a looping event that chops off the constant regions for IgM and IgD and form the IgG mRNAs. Any continuous looping occurrence will produce IgE or IgA mRNAs. In addition, cytokines are factors that have great effects on class switching of different classes of antibodies. Their interaction with B cells provides the appropriates signals needed for B cells differentiation and eventual class switching occurrence. For example, interleukin-4 induces the rearrangements of heavy chain immunoglobulin genes. That is IL- 4 induces the switching of Cμ to Cγ to Cκ
=== Chalcogenides and pnictides === The known chalcogenides of americium include the sulfide AmS2, selenides AmSe2 and Am3Se4, and tellurides Am2Te3 and AmTe2. The pnictides of americium (243Am) of the AmX type are known for the elements phosphorus, arsenic, antimony and bismuth. They crystallize in the rock-salt lattice.
Israeli airstrikes hit Iranian oil storage facilities, killing four people. Strikes on fuel depots near Tehran caused a "river of fire" to pour out along the streets, and the city became engulfed in thick black smoke, causing toxic acidic rain to fall in the surrounding area. US Central Command announced the death of a seventh US service member from an Iranian attack. The UK confirmed its forces had intercepted an Iranian drone headed towards Iraq, and declared its intention to send a Merlin helicopter to the region to detect aerial threats. According to the Iranian Red Crescent Society, 65 schools and 32 medical facilities had been targeted, and more than 10,000 civilian sites damaged. On 9 March, NATO confirmed the interception of a second ballistic missile in Turkish airspace. Turkey deployed six F-16s and air defense systems to Northern Cyprus. Trump claimed that "the war is very complete, pretty much", after speaking with Russian president Putin, and said "we already won the war in many ways." Following Syrian president Ahmed al-Sharaa's support for Lebanon's objective to disarm Hezbollah, the group targeted the city of Inkhil in Syria. About a dozen B-1B bombers arrived at bases in Europe.
==== Anti-Coercion Instrument ==== Several European leaders including France's Emmanuel Macron advocated using the EU's Anti-Coercion Instrument, a security and trade policy tool known as the "trade bazooka", to target the United States in retaliation. Under the not-previously-used instrument, the EU may adopt countermeasures, sometimes described as sanctions, including tariffs, restrictions on public procurement, and measures affecting trade and investment. Bernd Lange, chair of the European Parliament Committee on International Trade, supported its activation. By 21 January EU countries were described as being increasingly open to using the ACI against the United States, with Germany stating it will ask the Commission to explore its use.
Sources: en.wikipedia.org
== Interactions == Co-administration with erythromycin, ketoconazole, azithromycin, fluoxetine, or cimetidine resulted in elevated blood plasma concentrations of desloratadine and its metabolite 3-hydroxydesloratadine in studies. However, no clinically relevant changes were observed.
== History == Hardly anything is known about the King betta. Betta raja and Betta splendens cross bred in nature to create the King betta we know today. Others suppose that the King betta was bred from wild stock of B. raja.
Radioisotopes of iodine are called radioactive iodine or radioiodine. Dozens exist, but about a half dozen are the most notable in applied sciences such as the life sciences and nuclear power, as detailed below. Mentions of radioiodine in health care contexts refer more often to iodine-131 than to other isotopes. Of the many isotopes of iodine, only two are typically used in a medical setting: iodine-123 and iodine-131. Since 131I has both a beta and gamma decay mode, it can be used for radiotherapy or for imaging. 123I, which has no beta activity, is more suited for routine nuclear medicine imaging of the thyroid and other medical processes and less damaging internally to the patient. There are some situations in which iodine-124 and iodine-125 are also used in medicine. Due to preferential uptake of iodine by the thyroid, radioiodine is extensively used in imaging of and, in the case of 131I, destroying dysfunctional thyroid tissues. Other types of tissue selectively take up certain iodine-131-containing tissue-targeting and killing radiopharmaceutical agents (such as MIBG). Iodine-125 is the only other iodine radioisotope used in radiation therapy, but only as an implanted capsule in brachytherapy, where the isotope never has a chance to be released for chemical interaction with the body's tissues.
=== Computing and telecommunications === Adaptive delta modulation, a digital-to-analog data conversion technique Add-drop multiplexer, in optical fiber networks Administrative Template, in Microsoft Windows Group Policy deployment ADM-3A, a computer terminal manufactured by Lear Siegler Application development and maintenance in Lean IT Architecture Development Method, a component of The Open Group Architecture Framework Architecture-driven modernization of legacy software Automated decision-making
Sources: en.wikipedia.org
Though crude oil is predominantly composed of various hydrocarbons, certain nitrogen heterocyclic compounds, such as pyridine, picoline, and quinoline are reported as contaminants associated with crude oil, as well as facilities processing oil shale or coal and have also been found at legacy wood treatment sites. These compounds have a very high water solubility and thus tend to dissolve and move with water. Certain naturally occurring bacteria such as Micrococcus, Arthrobacter, and Rhodococcus have been shown to degrade these contaminants. Because petroleum is a naturally occurring substance, its presence in the environment is not necessarily the result of human causes such as accidents and routine activities (seismic exploration, drilling, extraction, refining and combustion). Phenomena such as seeps and tar pits are examples of areas that petroleum affects without human involvement.
=== Neuropathy and neurological diseases === Abnormal expression of CK1δ in brain tissue has been found in many diseases by immunohistochemistry and gene expression studies, like Alzheimer's disease, Down syndrome, progressive supranuclear palsy, parkinsonism dementia complex of Guam (PDC), Pick's disease, pallido-ponto-nigral degeneration (PPND) and Familial advanced sleep phase syndrome. In typical pathological tissues neuritic plaques (NPs) or granulovacuolar degeneration bodies (GVBs) of AD show high expression of CK1δ, whereas in neurofibrillary tangles (NFTs) expression of CK1δ is low. The AD hallmark proteins tau in NFTs or GVBs and TAR DNA-binding protein of 43 kDa (TDP-43) in GVBs colocalize with CK1δ. In vitro phosphorylation studies revealed that several sites within tau and TDP-43 were phosphorylated by CK1δ. Reduction of site-specific phosphorylation of TDP-43 by inhibition of CK1δ in both, a neuronal cell model as well as in a Drosophila model resulted in prevention of neurotoxicity and consequently to rescue of cells from cell death. Based on these studies, CK1δ could be recognized as a hallmark as well as a potential target for AD treatment and may be further useful for diagnostic and therapeutic purpose in the future. In addition, CK1δ plays a regulatory role in Parkinson's disease (PD) by phosphorylating α-synuclein. Familial advanced sleep phase syndrome (FASPS) is another neurological disease associated with CK1δ-mediated phosphorylation of the mammalian clock protein PER2.
=== Recombinant human growth hormone (rHGH) === In 1981, the new American corporation Genentech, after collaboration with Kabi, developed and started trials of recombinant human growth hormone (rHGH) made by a new technology (recombinant DNA) in which human genes were inserted into bacteria so that they could produce unlimited amounts of the protein. Because this was new technology, approval was deferred as lengthy safety trials continued over the next four years. In 1985, four young adults in the U.S. having received NPA growth hormone in the 1960s developed CJD (Creutzfeldt–Jakob disease). The connection was recognized within a few months, and use of human pituitary GH rapidly ceased. Between 1985 and 2003, a total of 26 cases of CJD occurred in adults having received NPA GH before 1977 (out of 7700), comparable numbers of cases occurred around the world. By 2003 there had been no cases in people who received only GH purified by the improved 1977 methods. Discontinuation of human cadaver growth hormone led to rapid Food and Drug Administration approval of Genentech's recombinant human growth hormone, which was introduced in 1985 as Protropin in the United States. Although this previously scarce commodity was suddenly available in "bucketfuls", the price of treatment (US$10,000–30,000 per year) was the highest at the time. Genentech justified it by the prolonged research and development investment, orphan drug status, and a pioneering post-marketing surveillance registry for tracking safety and effectiveness (National Cooperative Growth Study).
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.